In parallel, the serum from RA and SLE patients before RTX therapy promoted a pro‐inflammatory status in neutrophils, demonstrated by the increased expression of TF, IL‐8 and MCP‐1. This evidence concerns the gene CXCL8 and systemic lupus erythematosus.